[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564001":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":7,"locations":8,"responsibleParty":29,"collaborators":7,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":7,"eligibilityCriteria":37,"healthyVolunteers":33,"sex":38,"minAge":39,"maxAge":40,"enrollmentInfo":41,"targetDuration":7,"studyType":44,"phases":7,"briefSummary":45,"conditions":46,"keywords":7,"overallStatus":11,"whyStopped":7,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":59},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",null,[9],{"facility":10,"status":11,"city":12,"state":13,"zip":14,"country":15,"countryCode":16,"cosmosGeoPoint":17,"geoPoint":22,"contacts":23},"Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","RECRUITING","Shanghai","Shanghai Municipality","200000","China","CN",{"type":18,"coordinates":19},"Point",[20,21],121.45806,31.22222,{"lat":21,"lon":20},[24],{"name":25,"role":26,"phone":27,"phoneExt":7,"email":28},"yi xiang","CONTACT","13816967846","xiangyiht@163.com",{"type":30,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100564001","the-application-value-of-68ga-grazytracer-pet-in-immunotherapy-for-stage-iii-non-small-cell-lung-cancer-100564001",false,"NCT06623487","The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer","The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer: a Prospective, Observationa Trial","Inclusion Criteria:\n\n1. Patients with stage III NSCLC, after assessment according to clinical guidelines, require neoadjuvant immunotherapy;\n2. Fully-informed written consent obtained from patients;\n3. Patient ability to comply with protocol requirements;\n4. Age 18-75 years;\n5. Life expectancy of at least 6 months.\n\nExclusion Criteria:\n\n1. Patients with serious diseases that the investigator deems unsuitable for participation in the clinical study. Such as severe cardiopulmonary insufficiency, severe bone marrow suppression, severe hepatic or renal insufficiency, etc;\n2. Intestinal perforation, complete intestinal obstruction;\n3. Patients with uncontrolled diabetes mellitus or a fasting blood glucose value of ≥11 mmol\u002FL on the day of the test;\n4. Pregnant women and women who are potentially pregnant, as well as nursing mothers;\n5. Patients with poor compliance.","ALL","18 Years","75 Years",{"count":42,"type":43},30,"ESTIMATED","OBSERVATIONAL","Neoadjuvant immunotherapy can significantly improve the pathological complete response (pCR) and major pathological response (MPR) rates in resectable stage III non-small cell lung cancer (NSCLC), and extend the event-free survival (EFS). However, the current means for evaluating its efficacy are limited. This study aims to utilize the convenient and non-invasive 68Ga-grazytracer PET imaging to detect the aggregation of CD8+ T cells in target lesions after neoadjuvant immunotherapy for stage III NSCLC, and to assess its value in efficacy monitoring, providing valuable information for clinical treatment decisions.",[47,48,49],"Carcinoma, Non-Small-Cell Lung","PET \u002F CT","Neoadjuvant Immunotherapy","2024-09-29",{"date":52,"type":53},"2024-10-02","ACTUAL",{"date":55,"type":53},"2024-07-19",{"date":57,"type":43},"2027-07-31",{"name":5,"class":6},1]